Eye stem cell transplant could help restore vision in injured people

UlaJurkunas,associatedirectorofthecorneaserviceatMassEyeandEar,performsthefirstCALECsurgery.Courtesy Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor




hotspot

author：hotspot    Page View：46276
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： Special counsel raises new conflict of interest concerns for De Oliveira's lawyer
Next article： After affirmative action ruling, medical educators look to 'holistic review'